Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Thyroid Gland01:23

The Thyroid Gland

7.0K
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
7.0K
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

28
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
28
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

30
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
30
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

23
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
23
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

26
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

7.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidisciplinary management of advanced ovarian cancer in Spain: expert recommendations for achieving maximum survival and improving patient care.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexicoยท2026
Same author

Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.

ERJ open researchยท2026
Same author

The European society of pathology progress test: towards a European external quality control tool for pathology education.

Virchows Archiv : an international journal of pathologyยท2026
Same author

ARID1A deficiency reprograms the tumor secretome, enhancing microenvironmental remodeling and metastatic dissemination in endometrial carcinoma.

Cell death & diseaseยท2026
Same author

Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives.

Cancer treatment reviewsยท2026
Same author

The impact of the patient macroenvironment on molecular subgroups in endometrial cancer.

Cancerยท2026

Related Experiment Video

Updated: May 4, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K

Medullary thyroid carcinoma: a 25-year perspective.

Xavier Matias-Guiu1, Ronald De Lellis

  • 1Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida IRBLLEIDA, Av Alcalde Rovira Roure 80, Lleida, 25198, Spain, fjmatiasguiu.lleida.ics@gencat.cat.

Endocrine Pathology
|December 18, 2013
PubMed
Summary

Medullary thyroid carcinoma (MTC) is a C-cell neuroendocrine tumor with distinct features like amyloid deposits. RET mutations are key for early diagnosis and treatment, with surgery remaining the primary therapy.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.2K

Related Experiment Videos

Last Updated: May 4, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.2K

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Pathology

Background:

  • Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor arising from C-cells.
  • It exhibits characteristic morphology, including amyloid deposition.
  • Advances over 25 years have significantly improved understanding of MTC.

Observation:

  • MTC displays specific clinical, pathological, and molecular features.
  • Immunohistochemistry for calcitonin, CEA, CGRP, and TTF-1 aids in diagnosis.
  • RET mutations are crucial in both familial and sporadic MTC.

Findings:

  • Identification of RET mutations has revolutionized early diagnosis and treatment strategies for MTC.
  • Surgery is the established primary treatment modality for MTC.
  • Ongoing research into the molecular underpinnings of MTC is essential.

Implications:

  • Understanding MTC's molecular basis facilitates personalized treatment approaches.
  • Advances in diagnosis and treatment offer improved outcomes for MTC patients.
  • Further research into novel therapeutic strategies is warranted for individualized patient care.